Western Blot (WB)
(CDKN2A antibody (pAb) tested by Immunoprecipitation. 10 ul of CDKN2A antibody was used to immunoprecipitate CDKN2A from 400 ug of HeLa whole cell extract (lane 2). 10 ul of rabbit IgG was used as a negative control (lane 1). The immunoprecipitated protein was detected by Western blotting using the CDKN2A antibody at a dilution of 1:500.)
Rabbit anti-Human CDKN2A Polyclonal Antibody | anti-CDKN2A antibody
CDKN2A antibody (pAb)
IP: 10ul per IP
WB: 1:500-1:2,000 dilution
Western Blot (WB)
(CDKN2A antibody (pAb) tested by Immunoprecipitation. 10 ul of CDKN2A antibody was used to immunoprecipitate CDKN2A from 400 ug of HeLa whole cell extract (lane 2). 10 ul of rabbit IgG was used as a negative control (lane 1). The immunoprecipitated protein was detected by Western blotting using the CDKN2A antibody at a dilution of 1:500.)
Western Blot (WB)
(CDKN2A antibody (pAb) tested by Immunoprecipitation. 10 ul of CDKN2A antibody was used to immunoprecipitate CDKN2A from 400 ug of HeLa whole cell extract (lane 2). 10 ul of rabbit IgG was used as a negative control (lane 1). The immunoprecipitated protein was detected by Western blotting using the CDKN2A antibody at a dilution of 1:500.)
Western Blot (WB)
(CDKN2A antibody (pAb) tested by Western blot. Detection of CDKN2A by Western blot. The analysis was performed using 30 ug HeLa whole-cell extract and CDKN2A (pAb) at a 1:500 dilution.)
Western Blot (WB)
(CDKN2A antibody (pAb) tested by Western blot. Detection of CDKN2A by Western blot. The analysis was performed using 30 ug HeLa whole-cell extract and CDKN2A (pAb) at a 1:500 dilution.)
Background: CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A) is capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with COMMD1 and promotes its 'Lys63'-linked polyubiquitination. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development. Isoform 6 may be involved in regulation of autophagy and caspase-independent cell death; the short-lived mitochondrial isoform is stabilized by C1QBP. Multiple protein isoforms are encoded by this gene. The p16 isoform, also known as INK4a, is a CDK4 & CDK6 kinase inhibitor. It functions as negative regulator of the proliferation of normal cells and plays a role in aging and senescence.
NCBI and Uniprot Product Information
Observed: 20 kDa
NCBI Description
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
Uniprot Description
p16-INK4A: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported.
Protein type: Tumor suppressor; Cell cycle regulation; Nucleolus
Chromosomal Location of Human Ortholog: 9p21
Cellular Component: nucleoplasm; nuclear body; protein complex; mitochondrion; cytoplasm; nucleolus; nucleus; cytosol
Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; transcription factor binding; protein kinase binding
Biological Process: protein polyubiquitination; positive regulation of apoptosis; positive regulation of transcription, DNA-dependent; regulation of protein stability; negative regulation of B cell proliferation; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; cell cycle arrest; caspase activation; negative regulation of immature T cell proliferation in the thymus; transcription, DNA-dependent; protein destabilization; protein stabilization; negative regulation of cyclin-dependent protein kinase activity; negative regulation of cell-matrix adhesion; positive regulation of protein sumoylation; inhibition of NF-kappaB transcription factor; Ras protein signal transduction; negative regulation of ubiquitin-protein ligase activity; negative regulation of phosphorylation; negative regulation of protein kinase activity; positive regulation of transcription from RNA polymerase II promoter; positive regulation of DNA damage response, signal transduction by p53 class mediator; mitotic cell cycle; negative regulation of cell growth; negative regulation of transcription, DNA-dependent; rRNA processing; G1/S transition of mitotic cell cycle
Disease: Melanoma-astrocytoma Syndrome; Melanoma, Cutaneous Malignant, Susceptibility To, 2; Melanoma-pancreatic Cancer Syndrome
Research Articles on CDKN2A
Similar Products
Product Notes
The CDKN2A cdkn2a (Catalog #AAA388980) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The CDKN2A antibody (pAb) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's CDKN2A can be used in a range of immunoassay formats including, but not limited to, Immunoprecipitation (IP), Western Blot (WB). Applications Validated: IP: 10ul per IP WB: 1:500-1:2,000 dilution. Researchers should empirically determine the suitability of the CDKN2A cdkn2a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "CDKN2A, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
